Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

BACKGROUND: The oral Janus kinase (JAK) inhibitor baricitinib has demonstrated efficacy for severe alopecia areata (AA) over 36 weeks. There are limited data on the longer-term treatment of AA. OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of baricitinib for AA in adults w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Ohsang, Senna, Maryanne M., Sinclair, Rodney, Ito, Taisuke, Dutronc, Yves, Lin, Chen-Yen, Yu, Guanglei, Chiasserini, Chiara, McCollam, Jill, Wu, Wen-Shuo, King, Brett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974384/
https://www.ncbi.nlm.nih.gov/pubmed/36855020
http://dx.doi.org/10.1007/s40257-023-00764-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974384/
https://www.ncbi.nlm.nih.gov/pubmed/36855020
http://dx.doi.org/10.1007/s40257-023-00764-w

Ejemplares similares